+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID05752552

Phase 1 Study of Oral DO-2 for Safety and Pharmacokinetics in Adults with Advanced or Refractory Solid Tumors Including Non-Small Cell Lung Cancer with MET Mutation

Led by DeuterOncology · Updated on 2026-04-03

55

Participants Needed

13

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating DO-2, an investigational oral drug, in patients with advanced or treatment-resistant solid tumors that show MET gene changes and have no approved treatment options available. This first-in-human, open-label Phase 1 study includes two parts an initial dose escalation phase and an ongoing expansion phase focused on non-small-cell lung cancer NSCLC with a specific MET mutation. In the first part, patients receive increasing doses of DO-2 to determine safety and appropriate dosing using a stepwise method depending on side effects. In the second part, up to 30 patients with advanced NSCLC carrying the MET exon 14 skipping mutation, who have exhausted standard therapies, receive DO-2 orally once daily in 28-day cycles at the selected dose. Participants will be monitored for side effects and treatment-related adverse events over about 12 months. Researchers will assess tumor response using established criteria and track how long any response lasts, disease control, progression-free survival, and overall survival. Safety and drug behavior in the body will also be closely watched throughout the study period.

CONDITIONS

Brief Title

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Research Team

T

Timothy Perera, PhD

D

Desirée Kanters

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here